KT&G Wins Lawsuit Against Journalist Over Unfair Reporting

Regulations by 2FIRSTS.ai
Dec.19.2023
KT&G Wins Lawsuit Against Journalist Over Unfair Reporting
KT&G wins lawsuit against journalist accusing its subsidiary of unfair acquisition; Supreme Court dismisses appeal.

According to a report from South Korean news outlet Newsway, tobacco company KT&G has achieved a final victory in a lawsuit filed by a journalist and other media outlets regarding alleged unfair practices during the acquisition process of its subsidiary. The case has gone through two trials before this ultimate triumph.

 

Legal experts have revealed that on November 30th, the Supreme Court's First Civil Division upheld a decision to dismiss the appeal brought by KT&G against Kang Jin-gu, a former journalist of "Kyung-Hyang Shinmun," for damages.

 

The concept of non-acceptance of appeals refers to the system in which the Supreme Court dismisses appeals without reviewing the case.

 

Previously, on February 26, 2020, Kang published an article titled "KT&G Accused of Concealing New Drug Toxicity and Coercive Unfair Mergers" in "京乡新闻" magazine.

 

An article alleges that KT&G suppressed the toxicological test results of its subsidiary, KT&G Life Science Company, and manipulated the merger ratio by inflating the enterprise value during the merger with its subsidiary Yongjin Pharmaceutical in 2016.

 

The article also claims that KT&G Life Science Company has an illicit undisclosed agreement, whereby if the initial public offering of the merger case fails, compensation will be provided to investors of KT&G Life Science Company. Additionally, the CEO of the progressive pharmaceutical company opposing the merger was dismissed and replaced by someone from the headquarters of KT&G.

 

KT&G has filed a lawsuit seeking damages against Kang and others, alleging that their statements are false and have harmed the company's public perception.

 

In August 2022, the initial court recognized the public interest of the report but ruled that there was no reason to believe Jiang's claims of undisclosed agreements and concealed toxicity tests were true. The court also supported KT&G's view, stating that the report not only failed to raise any doubts but also used conclusory language to defame KT&G, and the opposing views were not adequately countered.

 

In the second trial held in July of this year, the court stated that the content in the article written by former journalist Mr. Kang, including claims of "reaching agreements with investors," "unfair dismissal of management executives," and "concealing genetic toxicity," were found to be false. The initial ruling was deemed justified, and therefore, the defendant's appeal was dismissed on grounds of lack of merit.

 

On November 30th, the Supreme Court unreasonably rejected the case, bringing an end to the 3-year, 10-month long litigation with KT&G emerging as the ultimate victor.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Alabama House Health Committee advances SB9 to restrict vaping in public spaces under Clean Indoor Air Act
Alabama House Health Committee advances SB9 to restrict vaping in public spaces under Clean Indoor Air Act
The Alabama House Health Committee passed Senate Bill 9 on Wednesday to restrict vaping in public areas under the state’s Clean Indoor Air Act. Introduced by Sen. Gerald Allen, SB9 would add vapes—defined as “electronic nicotine delivery systems”—to the forms of “smoking” currently prohibited in enclosed public places.
Feb.13 by 2FIRSTS.ai
San Francisco reaches $1 million settlement with nicotine pouch retailer Lucy Goods
San Francisco reaches $1 million settlement with nicotine pouch retailer Lucy Goods
In the United States, California, San Francisco City Attorney David Chiu announced a $1 million settlement requiring online tobacco retailer Lucy Goods, Inc. to stop shipping illegal tobacco products into San Francisco.
Jan.09 by 2FIRSTS.ai
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
2Firsts Interview | Bengt Wiberg: Why the Oral Health Risks of Nicotine Pouches Merit Further Study
As nicotine pouches gain global traction as a lower-risk alternative to smoking, questions are emerging about their potential oral health effects. In a 2Firsts interview, Stingfree AB founder Bengt Wiberg discusses why gum irritation and oral lesions warrant closer scrutiny within the broader framework of tobacco harm reduction.
Jan.06
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thai Health Authorities: Nicotine Pouches Classified as Tobacco; Sales Must Comply with 2017 Act
Thailand’s Disease Control Department has warned that nicotine pouches (“Snus”) are classified as tobacco products and must comply with the Tobacco Products Control Act B.E. 2560 (2017). Officials said they have received complaints about sales and promotional activities, and stressed that these products must not be displayed or promoted at points of sale.
Feb.02 by 2FIRSTS.ai
Haypp Reports 15% Q4 Sales Growth as Nicotine Pouch Volumes Rise
Haypp Reports 15% Q4 Sales Growth as Nicotine Pouch Volumes Rise
Haypp Group announced that net sales for October–December 2025 rose 15% year-on-year to SEK 1,052.2 million, or 19% in constant currency terms. The company recorded 28% volume growth in the nicotine pouch category during the quarter. The number of orders increased to 1.34 million, and active consumers rose to 630,000, marking the highest level in the company’s history. CEO Gavin O’Dowd said the company’s accelerating topline performance in the US and UK positions it for a strong 2026.
Market
Feb.22